Acceleron Pharma — Technical Presentation (December 2018)
18 slides from Acceleron Pharma's technical presentation, Dec 3, 2018
Slide 1: The MEDALIST Trial: Phase 3 Study of Luspatercept in MDS
Exhibit 99.2 The MEDALIST Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Patients With Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) Associated Anemia With Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transf
Slide 2: MEDALIST Trial Background and Rationale
MEDALIST Trial Background and Rationale • Patients with lower-risk (LR)a transfusion-dependent MDS have a poorer prognosis, with greater risk of progression to AML and inferior overall survival compared with patients with transfusion-independent MDS • RBC transfusion-dependent LR, non-del(5q) MDS pa
Slide 3: Luspatercept
MEDALIST Trial Luspatercept • Luspatercept is an investigational first-in-class erythroid maturation agent that neutralizes select TGF-β superfamily ligands to inhibit aberrant Smad2/3 signaling and enhance late-stage erythropoiesis in MDS models1 • In a phase 2 study in LR, non-del(5q) MDS, luspate
Slide 4: Study Design – A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study
MEDALIST Trial Study Design – A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Patient Population Luspatercept 1.0 mg/kg (s.c.) every 21 days • MDS-RS (WHO): ≥ 15% RS or ≥ 5% with SF3B1 n = 153 mutation Randomize Dose titrated up to a maximum of 1.75 mg/kg • < 5% blasts in bone marrow 2
Slide 5: Study Design (cont.)
MEDALIST Trial Study Design (cont.) • Patients were randomized between March 2016 and June 2017 at 65 sites in Belgium, Canada, France, Germany, Italy, the Netherlands, Spain, Sweden, Turkey, UK, and USA
Slide 6: Study Endpoints
MEDALIST Trial Study Endpoints Primary endpoint: • Red blood cell transfusion independence ≥ 8 weeks (weeks 1–24) Key secondary endpoint: • Red blood cell transfusion independence ≥ 12 weeks (weeks 1–24 and weeks 1–48) Additional secondary endpoints: • HI-E (IWG 2006 criteria1) for any consecutive 5
Slide 7: Demographics and Baseline Disease Characteristics
MEDALIST Trial Demographics and Baseline Disease Characteristics Luspatercept Placebo Characteristic (n = 153) (n = 76) Age, median (range), years 71 (40–95) 72 (26–91) Male, n (%) 94 (61.4) 50 (65.8) Time since original MDS diagnosis, median (range), months 44.0 (3–421) 36.1 (4–193) WHO classificat
Slide 8: Treatment Exposure
MEDALIST Trial Treatment Exposure Luspatercept Placebo Parameter (n = 153) (n = 76) Treatment duration, median (range), weeks 49 (6–114) 24 (7–89) Completed ≥ 24 weeks of treatment (primary phase), n (%) 128 (83.7) 68 (89.5) Completed ≥ 48 weeks of treatment, n (%) 78 (51.0) 12 (15.8) Number of dose
Slide 9: Primary Endpoint: Red Blood Cell Transfusion Independence ≥ 8 Weeks
MEDALIST Trial Primary Endpoint: Red Blood Cell Transfusion Independence ≥ 8 Weeks Luspatercept Placebo RBC-TI ≥ 8 weeks (n = 153) (n = 76) Weeks 1–24, n (%) 58 (37.9) 10 (13.2) 95% CI 30.2–46.1 6.5–22.9 P valuea < 0.0001 a Cochran–Mantel–Haenszel test stratified for average baseline RBC transfusion
Slide 10: Primary Endpoint: Subgroup Analysis
MEDALIST Trial Primary Endpoint: Subgroup Analysis Luspatercept, n (%) Placebo, n (%) OR (95% CI) P Value Overall 58/153 (37.9) 10/76 (13.2) 5.06 (2.28–11.3) < 0.0001 Average baseline RBC transfusion requirement ≥ 6 units/8 weeks 6/66 (9.1) 1/33 (3.0) 3.20 (0.37–27.7) 0.2699 < 6 units/8 weeks 52/87
Slide 11: Key Secondary Endpoint: RBC Transfusion Independence ≥ 12 Weeks
MEDALIST Trial Key Secondary Endpoint: Red Blood Cell Transfusion Independence ≥ 12 Weeks Luspatercept Placebo RBC-TI ≥ 12 Weeks (n = 153) (n = 76) Weeks 1–24, n (%) 43 (28.1) 6 (7.9) 95% CI 21.14–35.93 2.95–16.40 P valuea 0.0002 Weeks 1–48, n (%) 51 (33.3) 9 (11.8) 95% CI 25.93–41.40 5.56–21.29 P v
Slide 12: Duration of RBC-TI Response in Primary Endpoint Responders
MEDALIST Trial Duration of RBC-TI Response in Primary Endpoint Responders 1.0 Median duration (weeks) (95% CI): 30.6 (20.6–40.6) vs 13.6 (9.1–54.9) 0.9 Luspatercept 0.8 Placebo 0.7 Censored 0.6 0.5 RBC-TI 0.4 0.3 0.2 0.1 Probability Probability of Maintaining 0 0 10 20 30 40 50 60 70 80 90 100 110 1
Slide 13: Secondary Endpoint: Erythroid Response (HI-E)
MEDALIST Trial Secondary Endpoint: Erythroid Response (HI-E) Luspatercept Placebo (n = 153) (n = 76) Achieved HI-Ea (weeks 1–24), n (%) 81 (52.9) 9 (11.8) Reduction of ≥ 4 RBC units/8 weeks (baseline transfusion burden ≥ 4 units/8 weeks) 52/107 (48.6) 8/56 (14.3) Hb increase of ≥ 1.5 g/dL (baseline
Slide 14: Change in Hemoglobin Concentration
MEDALIST Trial Change3 in Hemoglobin Concentration Responder receiving luspatercept Non-responder receiving luspatercept Placebo 2 1 SE) FromBaseline (g/dL) ± 0 -1 11/5/2018Baseline 1 211/26/20183 12/17/20186 1/7/2019912 1/28/201913 2/18/201915 3/11/2019 18 4/1/2019 21 4/22/201924 Hb MeanChange( Ana
Slide 15: Safety Summary
MEDALIST Trial Safety Summary Luspatercept Placebo (n = 153) (n = 76) Patients with ≥ 1 TEAE, n (%) 150 (98.0) 70 (92.1) Patients with ≥ 1 serious TEAE 48 (31.4) 23 (30.3) Patients with ≥ 1 Grade 3 or 4 TEAE 65 (42.5) 34 (44.7) Patients with TEAEs leading to deatha 5 (3.3) 4 (5.3) Patients with ≥ 1
Slide 16: TEAEs ≥ 10% Incidence in Either Arm
MEDALIST Trial TEAEs ≥ 10% Incidence in Either Arm Luspatercept Placebo n (%) (n = 153) (n = 76) Fatigue 41 (26.8) 10 (13.2) Diarrhea 34 (22.2) 7 (9.2) Asthenia 31 (20.3) 9 (11.8) Nausea 31 (20.3) 6 (7.9) Dizziness 30 (19.6) 4 (5.3) Back pain 29 (19.0) 5 (6.6) Cough 27 (17.6) 10 (13.2) Edema periphe
Slide 17: Conclusions
MEDALIST Trial Conclusions • In lower-risk, RS-positive MDS, treatment with luspatercept resulted in a significantly higher percentage of patients who achieved RBC-TI, major RBC transfusion reduction, or hemoglobin increase, compared with placebo • Erythroid responses were durable, with approximatel
Slide 18: Acknowledgements
Acknowledgements • We thank all the patients, families, and investigators who participated in the study • This study was sponsored by Celgene Corporation, Summit, NJ, USA and Acceleron Pharma, Cambridge, MA, USA • The authors received editorial assistance from Excerpta Medica (Miriam de Boeck, Emily
Acceleron Pharma — Technical Presentation (December 2018) on 6ix